PIIIW — P3 Health Partners Inc.

P3 Health Partners Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Adjusted EBITDA: $26 million, significantly improved from a loss of $22 million in Q1 2025.
• Revenue: $386 million, up from $373 million year-over-year, despite a decline in membership.
• At-risk Membership: Approximately 106,000, down from 118,000 in Q1 2025 due to strategic exits from underperforming contracts.
• Medical Margin: $74 million with a medical loss ratio of 85.2% (adjusted).
• Cash Position: Ended the quarter with $25 million in cash and equivalents.
• Revised Full-Year 2026 Adjusted EBITDA Outlook: Increased to a range of $20 million to $60 million, with a midpoint of $40 million.

2. Strategic Updates and Business Highlights

• Operational Improvements: Focus on contract restructuring, operational redesign, and alignment between clinical and financial infrastructure has led to improved performance.
• Payer Contract Enhancements: Improved risk funding and cost accountability structures have resulted in a 15% year-over-year increase in Medicare Advantage funding rates.
• Clinical Execution: Enhanced medical cost management and quality execution are yielding positive results, with a flat medical expense trend compared to a 7% trend seen in peers.
• Partnership Expansion: New partnership in Nebraska added 28,600 lives under management, demonstrating a disciplined growth strategy.

3. Forward Guidance and Outlook

• The company is optimistic about the Medicare Advantage environment, anticipating continued margin expansion opportunities.
• The focus will remain on improving operational execution and expanding payer relationships with a pathway to deeper delegation.
• The revised outlook reflects confidence in the underlying operating trajectory and structural improvements made.

4. Bad News, Challenges, or Points of Concern

• Membership Decline: The drop in at-risk membership indicates a strategic shift that may pose risks to revenue stability in the short term.
• Dependence on Payer Relationships: Future success hinges on maintaining and expanding partnerships, particularly in achieving deeper delegation with payers.
• Market Competition: The industry is experiencing increasing competitive pressures, with peers guiding to higher medical cost trends, which P3 aims to counteract through operational efficiency.

5. Notable Q&A Insights

• Utilization Management: Discussion around the impact of Part A and B costs showed proactive management in reducing costs, particularly in Part B.
• Payer Partner Expansion: The improved financial position and balance sheet are expected to enhance P3's attractiveness as a partner, facilitating future growth.
• Delegation Pathway: The delegation process is gradual and requires meeting specific contractual milestones, indicating a cautious but structured approach to expanding operational control.

Overall, P3 Health Partners demonstrated strong financial performance in Q1 2026, driven by strategic operational improvements and a focus on clinical execution, while navigating challenges related to membership and competitive pressures. The outlook remains positive, with a clear focus on enhancing payer relationships and operational efficiency.